Intraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 1—ELIOT by unknown
REVIEW ARTICLE – BREAST ONCOLOGY
Intraoperative Radiation Therapy: A Critical Analysis of the
ELIOT and TARGIT Trials. Part 1—ELIOT
Melvin J. Silverstein, MD1,2, Gerd Fastner, MD3, Sergio Maluta, MD4, Roland Reitsamer, MD5, Donald A. Goer,
PhD6, Frank Vicini, MD7, and David Wazer, MD8,9
1Breast Center, Hoag Memorial Hospital Presbyterian, Newport Beach, CA; 2Department of Surgery, Keck School of
Medicine, University of Southern California, Los Angeles, CA; 3Radiotherapy and Radio-Oncology Landeskrankenhaus,
Paracelsus Medical University, Salzburg, Austria; 4Radiation Oncology, Oncological Hyperthermia Unit—Medical Center,
Verona, Italy; 5Department of Senology, Paracelsus Medical University Salzburg, Salzburg, Austria; 6Physics, IntraOp
Medical, Sunnyvale, CA; 7Radiation Oncology, St. Joseph Mercy Oakland, Pontiac, MI; 8Radiation Oncology, Tufts
University School of Medicine, Boston, MA; 9Radiation Oncology, Albert Medical School of Brown University,
Providence, RI
ABSTRACT
Introduction. Two randomized intraoperative radiation
therapy trials for early-stage breast cancer were recently
published. The ELIOT Trial used electrons (IOERT), and
the TARGIT-A Trial Update used 50-kV X-rays (IORT).
These studies were compared for similarities and differ-
ences. The results were analyzed and used to determine
which patients might be suitable for single-dose treatment.
Method. The primary sources of data were the ELIOT
Trial and TARGIT-A Trial, as well as a comprehensive
analysis of the peer-reviewed literature of accelerated
partial breast irradiation (APBI) using 50-kV X-rays or
electrons. Studies published or presented prior to March
2014 were analyzed for efficacy, patient restrictions,
complications, and outcome.
Results. With a median follow-up of 5.8 years, the 5-year
recurrence rates for ELIOT versus external beam radiation
therapy (EBRT) patients were 4.4 % and 0.4 %, respec-
tively, p = .0001. A low-risk ELIOT group was identified
with a 5-year recurrence rate of 1.5 %. With a median
follow-up of 29 months, the 5-year recurrence rates for the
TARGIT-A versus EBRT patients were 3.3 % and 1.3 %,
respectively, p = .042.
Conclusion. With 5.8 years of median follow-up, IOERT
appears to have a subset of low-risk women for whom
IOERT is acceptable. With 29 months of median follow-up
the results of IORT with 50-kV devices are promising, but
longer follow-up data are required. At the current time,
single-fraction IOERT or IORT patients should be treated
under strict institutional protocols.
When breast conserving surgery (BCS) is chosen, excision
is commonly followed by 5 weeks of whole breast irradiation
(WBI), with or without a boost to the tumor bed. Long radi-
ation schedules are a burden for many women.1,2 This has
stimulated an interest in accelerated partial breast irradiation
(APBI) that can reduce overall treatment time without com-
promising oncological outcomes or cosmesis.3,4 Intra-
operative radiation therapy (IORT) is an attractive APBI
approach because it delivers the entire radiation treatment
during surgery. Two randomized IORT-APBI trials, ELIOT
using electrons and TARGIT-A using 50-kV X-rays, have
studied whether IORT can produce results that are equivalent
to standard treatment.5–7 In a series of 2 reports, we analyze
these studies to determine whether IORT is ready for incor-
poration into standard practice and to determine what patient
cohorts might be suitable for single-dose treatment.
METHODS
The primary sources of data for these analyses were the
ELIOT Trial and TARGIT-A Trials, as well as a compre-
hensive review of peer-reviewed literature of APBI studies
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using 50-kV X-rays or electrons, involving 50 or more
patients with a minimum of 30 months median follow-up.5–7
Since the energy source for intraoperative radiation
therapy and the technique used for delivery is different for
ELIOT and TARGIT-A, each study is discussed in a sep-
arate report. The Results Section for each trial summarizes
outcomes reported in the trial publications. The Discussion
Section uses other studies as well as the trial publications to
assess efficacy of the treatment and provide guidance on
their use in non-trial environments. Intraoperative radiation
therapy given with electrons (ELIOT) is referred to as
IOERT. Intraoperative radiation therapy given with 50-kV
x-rays (TARGIT A) is referred to as IORT.
ELIOT TRIAL
Overview
The ELIOT Trial randomized 1,305 patients, 48 years or
older, with tumors 2.5 cm or smaller to either a single dose
of 21 Gy prescribed to the 90 % depth or to 50 Gy of
external beam radiation therapy (EBRT) and a 10-Gy boost
delivered over 6 weeks.5 With a median follow-up of
5.8 years, the 5-year recurrence rate was 4.4 % for ELIOT
versus 0.4 % for the EBRT (p \ .0001). The data are
summarized in Table 1.
Technique 8
After tumor excision, the breast tissue was mobilized. The
chest wall and underlying structures were protected with a
lead/aluminum shield. The breast tissue to be irradiated was
reapproximated over the shield. An appropriately sized
collimator (4–8 cm) was inserted. Radiotherapy was per-
formed using a linear accelerator; 21 Gy, to the 90 %
isodose, was delivered to the tumor bed.
Complications
Compared with the conventional arm, ELIOT reported
less skin damage (i.e., erythema, dryness, hyper-pigmen-
tation, or itching), p = .0002, and no differences for
fibrosis, retraction, pain or burning, but a higher incidence
of radiologically determined fat necrosis, 5 %, versus 2 %,
p = .04. In addition, ELIOT had less pulmonary toxicity
than the EBRT as diagnosed by follow-up spiral CT (4 in
the ELIOT arm and 38 in the EBRT arm). These differ-
ences in skin and pulmonary toxicity are not unexpected
given the differences in IOERT versus EBRT breast irra-
diation techniques.
Local Recurrences
The 5-year ipsilateral breast tumor recurrence (IBTR)
rates exceeded 10 % for patients with tumors[2 cm (10 of
83, 10.9 %), 4 or more positive nodes (4 of 31, 15.0 %),
poorly differentiated tumors, i.e., grade 3 (15 of 129,
11.9 %), estrogen receptor negative tumors (8 of 63,
14.9 %), or triple negative disease (7 of 43, 18.9 %).
Patients with a high proliferative index, i.e., Ki-67 [ 20 %,
trended to a high IBTR rate (22 of 244, 9.1 %) but did not
reach the 10 % threshold. The 5-year IBTR was 11.3 % for
the 199 women (30.6 %) with 1 or more of these risk
factors vs 1.5 % for the 452 women (69.4 %) with none of
these factors (ELIOT Low Risk). The per-protocol results
were similar to the intent-to-treat analysis. The IBTR was
4.7 % versus 0.5 % for ELIOT versus EBRT; the 5-year
IBTR was 11.8 % for the 178 women (30.4 %) with 1 or
more risk factors versus 1.7 % for the 407 ELIOT Low
Risk women (69.6 %).
Regional Failures
Greater regional failure with ELIOT (9 patients, 1.0 %)
versus EBRT (2 patients, 0.3 %), p = .03, raised concern
that fewer regional recurrences with EBRT might be par-
tially due to lower axillary coverage by the tangential
breast irradiation.
Patients with 4 or More Positive Nodes
A total of 69 patients with 4 or more positive nodes
received additional EBRT of 50 Gy to the axilla. Those
randomized to EBRT received axillary irradiation










IBTR 4 0.4 % 35 4.4 % \.0001
Local (‘‘true’’) 4 0.4 % 21 2.5 % .0003
Elsewhere 0 0 14 1.9 % .0001
Axillary/regional 2 0.3 % 9 1.0 % .03
Contralateral breast
cancer
13 1.7 % 8 1.1 % .34
Distant metastases 35 4.8 % 33a 5.1 % .94
Other primary cancer 22 3.2 % 20 2.5 % .88
Deaths (total) 31 3.1 % 34 3.2 % .59
Breast cancer 20 2.0 % 23 2.1 % .56
Other 11 1.1 % 11 1.1 % .94
Adapted from Table 2, Lancet Oncology5
a 4 IOERT patients diagnosed with metastases at the time of surgery
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concurrently. Axillary irradiation was delayed 6–
12 weeks for IOERT patients. Timing of adjuvant che-
motherapy administration for these patients was not
specified.
Elsewhere Recurrences
There were 14 (1.9 %) versus no (zero) ipsilateral
‘‘elsewhere’’ recurrences with ELIOT vs EBRT, p \ .0001.
Contralateral Breast Cancer
There was a nonsignificant higher contralateral breast
cancer rate in the EBRT group vs ELIOT (13 vs 8 patients).
Metastatic Breast Cancer
Metastases, other primary cancers, breast cancer death,
and other deaths were similar in the 2 groups (Table 1).
Survival
Overall survival at 5 years was identical, 96.8 % for the
ELIOT group vs 96.9 % for the EBRT group. The 10-year
survival remained similar (89.8 % for ELIOT and 92.0 %
for EBRT patients).
DISCUSSION
The ELIOT trial closed in December 2007. Analysis of
the results began 5 years after accrual of the last patient.
This is important since the time to local recurrence after
radiation therapy combined with adjuvant treatment can be
delayed.9,10 Overall, ELIOT patients had a higher 5-year
recurrence rate than EBRT patients (4.4 % vs 0.4 %,
p = .0001). However, ELIOT patients can be divided into
low- and high-risk groups based on tumor size, receptor
status, nodal positivity, and grade. ELIOT Low-Risk
women (69.4 % of the ELIOT patients) had a 5-year IBTR
rate of only 1.5 % compared with 11.3 % for the 30.6 % of
ELIOT patients with 1 or more high-risk factors.
The American Society of Therapeutic Radiologists
(ASTRO) has also published a set of criteria for selecting
patients who are suitable for APBI.11 For the 23 % of the
ELIOT patients who were ASTRO suitable for APBI, the
IBTR was 1.5 % at 5 years and equivalent to the IBTR for
the EBRT-suitable patients.12 The low recurrence for
ASTRO-suitable women is consistent with a large series of
patients treated with ELIOT off-protocol at the European
Institute of Oncology (EIO).13,14 Table 2 shows local relapse
rates for Out-Trial patients using the ASTRO and ESTRO
APBI criteria and for favorable luminal A biology
patients.11,15 The Out-Trial results show low 5-year recur-
rence rates for ASTRO suitable, ESTRO good, and Luminal
A women, suggesting that favorable tumor biology might
allow IOERT to obtain acceptable results in patients
unsuitable for APBI by ASTRO or ESTRO guidelines.
The University of Verona reported only 1 recurrence at a
mean follow-up of 46 months in 226 low-risk women
treated with 21 Gy to Dmax (about 10 % lower dose than
used in the ELIOT Trial).16 Updated results, first presented
at the San Antonio Breast Cancer Symposium in 2012,
showed only 4 recurrences (1.8 %) with a mean follow-up
of 51 months.17 The median follow-up is now 5 years with
no further recurrences.
In ELIOT patients, 14 of 35 (40 %) of the ipsilateral
recurrences were ‘‘elsewhere’’ recurrences, raising the
TABLE 2 Analysis of Out-
Trial ELIOT patients by
ASTRO and ESTRO Guidelines
for APBI
Adapted from Leonardi13,14 and
with permission of Springer
Science & Business Media24
All Suitable Cautionary Unsuitable Not
accessible
ASTRO guidelines
Patients 1822 295 (16 %) 690 (38 %) 812 (45 %) 25 (1.0 %)
Local relapses 76 3 21 50 2
5-year rate 6.0 % 1.5 % 4.4 % 8.8 % 9.9 %
Luminal A 648 (36 %) 118 (40 %) 271 (39 %) 251 (31 %) 8
Local relapse 8 2 3 3 0
5-year rate 1.7 % 2.3 % 1.6 % 1.6 % –
ESTRO guidelines
Patients 1822 572 (31 %) 268 (15%) 965 (53 %) 17 (1 %)
Local relapses 76 7 12 56 1
5-year rate 6.0 % 1.9 % 7.1 % 7.8 % 6.6 %
Luminal A 648 (36 %) 206 (36 %) 129 (48 %) 306 (32 %) 8
Local relapse 8 0 2 6 0
5-year rate 1.7 % 0 % 2.5 % 2.4 % –
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question of whether the applicator size might have been too
small to adequately treat microscopic disease extending
beyond the excised tumor. The ELIOT authors write: ‘‘The
difficulty (with IOERT APBI) is not only to define patients
at low risk of harboring microscopic disease beyond the
tumor site, but also to define the proper coverage of the
tumor bed.’’5
This hints that larger applicators may have reduced
recurrence rates, a concern confirmed by Leonardi et al.13
Noting the 4-cm median applicator size used in the ELIOT
Out-Trial study and that the pattern of recurrences indi-
cated neoplastic tumor foci outside the effective radiation
field, she stated that they were planning to increase the field
size used in ELIOT. With a 4-cm applicator, despite the
IOERT surgical preparation bringing almost 2 cm of sur-
rounding tissue under the applicator, only about 1.5 cm of
surrounding tissue is irradiated to the prescription dose of
90 % because electron applicators have cold spots in the
field periphery. Krechetov estimates that, depending on the
energy, a 4-cm applicator covers at most only 55 % of the
clinical treatment volume (‘‘CTV’’) to the 90 % prescrip-
tion dose.18 To ensure uniform coverage of microscopic
residual disease, the IOERT applicator should have a cir-
cumferential dimension at least 1.5 to 2 cm larger than the
maximum tumor dimension. The applicator sizes used in
the ELIOT Trial are not specified, but the current guide-
lines for ELIOT at the EIO (Table 3) indicating larger field
sizes, as suggested by Leonardi, are now preferred.13
In Verona, where applicator size was selected to be
approximately 2 cm circumferentially larger than the
largest tumor dimension, median applicator size was 6 cm,
87 % were [5 cm, and 31 % were [6 cm, ensuring good
coverage of the tumor bed.17
The lower dose used in Verona has lower toxicity and
results in a higher percentage of the clinical treatment
volume receiving the prescription dose. The higher dose
used in the ELIOT study has acceptable toxicity at 5 years,
but the higher ELIOT dose could impact longer-term cos-
mesis, especially when larger applicators are used.12
In the ELIOT Trial, 53 of 651 (8.1 %) of the IOERT
patients had invasive lobular carcinoma (ILC).5 ILC is
generally excluded in APBI trials. In the ELIOT study, ILC
did not surface as an ELIOT high-risk factor, but 5 of 35
(14.3 %) of the total IOERT recurrences were from ILC or
mixed IDC/ILC patients. Maluta, comparing his APBI
patients with those in the ELIOT Out-Trial, found that ILC
might be a risk factor (p = .04) in patient selection.16,19
The current ELIOT policy at the EIO permits ILC only
after MRI assessment (Table 3).
Univariate analysis in the ELIOT Out-Trial showed that
3 or more positive nodes was a risk for recurrence, but not
a factor in the multivariate analysis.19 However, annual
rates of recurrence with 3 or more positive nodes compared
unfavorably with patients with 0 or 1–2 positive nodes: for
true recurrences (1.57 vs 0.69 % or 0.70 %), ipsilateral
breast elsewhere recurrences (1.35 % vs 0.29 % or
0.69 %), and annual rates of breast cancer deaths (2.97 vs
0.52 % or 0.70 %).19 The University of Verona included
50 patients (22.1 %) that had either a positive SNB at the
time of surgery or final pathology who also underwent
complete axillary lymph node dissection during the initial
surgery or at a second operation.16 A total of 38 patients
had 1 positive lymph node and 12 had 2. All received
IOERT. None of the recurrences at 5 years (Table 4) had a
positive sentinel node. In the ELIOT Trial patients were
stratified as N0, 1–3 positive nodes, or 4 or more positive
nodes.5 The presence of 4 or more positive nodes dis-
qualified a patient as ELIOT Low Risk. Patients with 1–3
positive nodes had a 5-year recurrence rate of 5.3 %, and
10 of 35 (28 %) of the recurrences came from this group. It
would have been instructive to see if patients with only 1 or
2 positive nodes had a lower recurrence rate as the ELIOT
Out-Trial suggests.19 It would also allow treatment deci-
sions to be made per the American Society of Breast
Surgeons guidelines based on the ACOSOG Z0011 treat-
ment of patients with 1 or 2 positive nodes.20,21
Some IOERT APBI centers perform definitive node
assessment in a separate out-patient surgery prior to tumor
removal, and only patients with pN0 receive IOERT APBI.
While this resolves nodal status, it subjects all patients to a
second surgical procedure that 70–75 % will not require.
Margins are not discussed, but we know from previous
ELIOT presentations that the positive margin rate was very
low: only 3 (0.5 %) in the ELIOT arm and 9 (1.4 %) in the
EBRT arm.22 Other centers treating with IOERT APBI that
find positive margins either re-excise or ignore them, with
no apparent impact on recurrence reported to date. In the
Maluta study, none of the 16 patients (7.1 %) with positive
margins or the 17 patients (7.5 %) with close margins have
recurred.16 Jobsen has demonstrated that margin positivity
TABLE 3 Reported guidelines at the EIO for low-risk IOERT Group
Age C60 years
Tumor size \2 cm
Applicator size 6 cm minimum, 5 cm occasionally
Grade G1/G2
ER status ER?
Proliferative index Ki-67 \ 20
Biology Luminal A
Lobular CA Only with MRI assessment
As reported at ISIORT 2012, Baveno, Italy, and with permission of
Springer Science & Business Media24
Patients found with higher risk factors post-IOERT will also receive 8
fractions of 3.6–4.0 Gy of EBRT, excluding the breast volume irra-
diated by IOERT
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in older women does not seem to impact recurrence.23
More data are needed to determine the impact of positive
margins on recurrence.
APBI requires proper patient selection and proper
technical implementation. The ELIOT Trial and other
APBI IOERT published studies show a probable subset of
women who can safely benefit from this 1-day treatment.
These are the ELIOT Low Risk, ASTRO suitable, ESTRO
good, or Luminal A patients. The current guidelines for
ELIOT at the EIO are shown in Table 3.
The ELIOT authors suggest that preoperative criteria
(e.g., tumor size, age, and pathological and biological
examination of the biopsy specimen) can be used to iden-
tify suitable patients. A second option, they say, would be
to treat all patients with IOERT, and after postsurgical
categorization, give WBI to patients at high risk for
recurrence. However, this is technically challenging, as the
WBI should avoid overlap with the volume of tissue irra-
diated with IOERT. The better solution is to select APBI
patients who are suitable for IOERT and who can then be
expected to have low 5-year recurrence rates with no
adverse impact on overall survival.
ELIOT CONCLUSIONS
The ELIOT trial has contributed to our understanding of
whether a single-dose treatment using electrons may be
possible. The Trial included some high-risk patients that
today would not be considered a good choice for APBI. It
appears, however, that IOERT APBI may have a subset of
low-risk women (ASTRO suitable, ELIOT Low Risk,
Luminal A) for whom IOERT could be effective, with a
recurrence rate in the 2 % range at 5 years. In spite of a
5.8-year median follow-up, the ELIOT data are still early
and single-fraction IOERT patients should be treated under
strict institutional protocols. When long-term results are
available, it is likely there will be a higher overall recur-
rence rate for IOERT when compared with EBRT, but we
should be able to select subgroups of favorable patients
where this difference is small and acceptable. How much
additional risk of local recurrence is acceptable will vary
with patients and the situation in which they find them-
selves. Overall, the results of the ELIOT Trial are
reasonably mature and encouraging.
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